Hero - CBC vs CBD
Home/Compare/CBC vs CBD

CBC vs CBD: Zero Human Trials, and Two Studies That Disagree

CBC is the third branch of the cannabis biosynthetic pathway, alongside THC and CBD. It is not intoxicating, and its most potent measured action is at TRPA1, a sensory ion channel, where it is the strongest phytocannabinoid tested. Beyond that, honesty requires saying that CBC has never been tested in a controlled human trial, and that two respected labs disagree about whether it activates CB1 at all.

Third Party TestedBatch Certificates Of AnalysisHighest QualityFull SpectrumGlobal Shipping100% Organic
Third Party TestedBatch Certificates Of AnalysisHighest QualityFull SpectrumGlobal Shipping100% Organic

At a glance

Property
CBC
CBD
CB1 receptor
Disputed. One study reports no activation, another reports Ki 11 nM
Very weak, no activation
CB2 receptor
CB2-preferring agonist, Ki 27 nM
Ki 240 nM, low efficacy
Most potent target
TRPA1, EC50 approximately 0.09 μM, among the most potent tested
ENT1 adenosine transporter, plus TRPA1 at 0.09 μM
Intoxicating
No
No
Origin
CBGA to CBCA via CBCA synthase, then decarboxylation
CBGA to CBDA via CBDA synthase, then decarboxylation
Human trials
None
Dozens
Human pharmacokinetics
None
Partially characterized
Approved medicine
None
Epidiolex

The disagreement worth knowing about

Most articles about minor cannabinoids present a tidy picture. The real literature on CBC is not tidy, and pretending otherwise would be misleading.

A 2019 paper in the British Journal of Pharmacology reported that CBC does not activate CB1 at all, and is instead a selective CB2 agonist with higher efficacy than THC at that receptor. A 2020 paper in Scientific Reports reported the opposite: a CB1 binding affinity of 11 nanomolar, which would make CBC the highest-affinity minor cannabinoid tested, along with functional activity.

Both cannot be right. The likely explanation is assay differences. The 2020 dataset used partial displacement of a radioligand, which its own authors flagged as not directly comparable to a full-displacement measurement. But it is not resolved.

The correct thing to say is that CBC is a CB2-preferring agonist, and that its CB1 activity is disputed between studies. Anyone who states a single confident CBC binding figure is quoting one paper and ignoring the other.

There is a further wrinkle that almost nobody mentions. A 2025 paper showed that the two mirror-image forms of CBC behave differently: one activates CB2 and the other does not. CBC in plant material and synthetic products is not necessarily a single form, so the potency of bulk CBC depends on how it was made.

Where CBC is genuinely potent

Inner - CBC vs CBD

CBC’s standout property is TRPA1 activation, with an EC50 of 0.09 micromolar. That is among the most potent TRPA1 actions measured for a phytocannabinoid, and it is comparable to CBD’s own TRPA1 activity, so it is a shared strength rather than a point of difference. TRPA1 is a sensory channel involved in detecting irritants and in inflammatory signaling.

Interestingly, when researchers looked at CBC’s anti-inflammatory and gut motility effects in mouse colitis models, those effects went through TRPA1 rather than through cannabinoid receptors. So the cannabinoid receptor argument above may matter less than it appears.

CBC also inhibits cellular uptake of anandamide, one of the body’s own cannabinoids, more effectively than CBD does.

What the research shows, and does not

CBD
CBD has an extensive human trial record, some of it positive and some of it not.
Three epilepsy trials good enough to produce an FDA-approved medicine.
Fifteen of sixteen randomized pain trials showing no benefit over placebo.
A modest anxiety signal in meta-analysis at high acute doses.
CBC
CBC has zero controlled human trials. Not one.
Everything published about CBC comes from cell culture and rodent studies, including the anti-inflammatory work, the antimicrobial work and the neurogenesis work that occasionally gets cited in marketing copy.
There is also no human pharmacokinetic data for CBC. Nobody has published what happens to it after you swallow it.

This does not mean CBC is useless. It means nobody knows, and a company selling it should say so plainly rather than filling the gap with mouse studies dressed up as findings.

What people get wrong

01CBC is a powerful anti-inflammatory.
In mice, via TRPA1. Not tested in people.
02CBC promotes neurogenesis.
From a rodent study on neural stem progenitor cells. Not tested in people.
03CBC has the strongest CB2 binding of any cannabinoid.
One study says something close to this. Another says its CB2 EC50 is above 3 micromolar. Take your pick, and note that you are picking.
04CBC and CBD work together.
No study has tested that combination in humans, and the general entourage hypothesis has not held up in the experiments designed to test it.

Choosing between them

If you want the compound with human evidence, that is CBD. If you want to try CBC, you are trying something with interesting receptor pharmacology and no clinical data at all, at a dose nobody has characterized.

CBC appears naturally in full-spectrum hemp extracts at low levels. A dedicated CBC product concentrates it. Neither approach has evidence behind it in humans.

Still weighing up the options? See CBC vs CBG, CBN vs CBC or CBD vs CBG vs CBN. For more background, read our guide on the entourage effect. Endoca products related to this comparison: Full-spectrum CBD.

How Endoca tests for this

CBC appears on our full-spectrum certificates of analysis alongside CBD, CBDA, CBG, CBN, THC and THCA. In our extracts it is a genuine minor constituent at low percentage. We report the measured number rather than a target, and we do not build claims on top of it.

Frequently asked questions

No. In animal behavioral testing it produced no cannabis-like effects.

At CB2 and TRPA1, on paper, in cell assays. In terms of anything demonstrated in a person, there is nothing to compare.

Unknown. No human pharmacokinetic or dosing study exists.

Usually in small amounts, yes.

CBC is scarce and difficult to isolate in quantity, and research funding has concentrated on CBD and THC.

CBC is a minor cannabinoid that the hemp plant makes from CBGA, the same precursor that leads to CBD and THC. It is present in much smaller amounts than CBD and is not considered intoxicating.

Not in people. The research on CBC is from cell and animal studies, and there are no published human trials. Any benefit claimed for CBC is a hypothesis, not a finding.

References

01

Udoh M, Santiago M, Devenish S, McGregor IS, Connor M. Cannabichromene is a cannabinoid CB2 receptor agonist. Br J Pharmacol 2019;176:4537-4547.

02

Zagzoog A et al. In vitro and in vivo pharmacological activity of minor phytocannabinoids. Sci Rep 2020;10:20405.

03

De Petrocellis L et al. Effects of cannabinoids on TRP channels. Br J Pharmacol 2011;163:1479-1494.

04

Walsh KB, McKinney AE, Holmes AE. Minor Cannabinoids. Front Pharmacol 2021;12:777804.

05

Udoh M et al. Enantiomers of cannabichromene at CB2. Cannabis Cannabinoid Res 2025;10.

06

Congressional Research Service. Legal Sidebar LSB11381, updated 22 December 2025.

Last reviewed 1 September 2026.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.